Skip to content

Effects of peptide ingestion on sleep: a randomized, double-blind, placebo-controlled, parallel-group study

Effects of peptide ingestion on sleep: a randomized, double-blind, placebo-controlled, parallel-group study - Effects of peptide ingestion on sleep

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000043407
Enrollment
70
Registered
2021-02-24
Start date
2021-02-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intake of the peptide foods for 2 weeks Intake of the placebo for 2 weeks

Sponsors

Leverage Brain Inc.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Males and females aged 30-64 years old 2) Subjects who have received a full explanation of the study, understand its contents, and have given their written consent to participate in the study

Exclusion criteria

Exclusion criteria: 1) Subjects who are undergoing medical treatment or diagnosed as needing medical treatment 2) Subjects who are pregnant, lactation, or planning to become pregnant during this study 3) Subjects who have history of serious disorders (Cerebrovascular disease, Cardiac disorder, Hepatic disorders, Gastrointestinal disorder, Endocrine-related disorder, etc.) 4) Subjects who have or have a history of sleep disorders such as insomnia or sleep apnea syndrome (SAS) 5) Subjects with medication allergies, food allergies, or a serious history of such allergies 6) Subjects who have or have a history of drug addiction or alcoholism 7) Subjects who are judged by the principal investigator to have an irregular lifestyle 8) Subjects who regularly use medicines, supplements, etc. 9) Subjects who urinate more than 3 times during the night 10) Extremely heavy drinkers (more than 60g/day of alcohol) 11) Subjects who have participated in other drug or food trials within the past month, or are willing to participate during this study 12) Subjects who are judged as ineligible to participate in this study by the principal investigator

Design outcomes

Primary

MeasureTime frame
Evaluation of OSA Sleep Inventory MA version after 2 weeks of intake

Secondary

MeasureTime frame
Evaluation of the following items after 2 weeks of intake 1) questionnaires about stress and quality of life 2) salivary markers

Countries

Japan

Contacts

Public ContactShigeru Imai

Leverage Brain Inc. Clinical Trial Department

imai@levbrain.com080-7290-0404

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026